Jiangsu Hengrui Sets Tenth Board Session with Director Changes and New INED
I'm PortAI, I can summarize articles.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced the formation of its tenth board session, proposing an eleven-member board with six executive directors, one non-executive director, and four independent non-executive directors, pending shareholder approval at the 2025 AGM. The company plans to re-elect most existing directors while independent director Dong Jiahong will retire. Lou Liguang is proposed as a new independent director to enhance oversight. The stock is rated a Buy with a target price of HK$96.90.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments